Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

Overview

The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events after percutaneous coronary intervention (PCI) and stent implantation.

Full Title of Study: “Safety and Efficacy of Ticagrelor With Low-dose Aspirin Versus Regular Aspirin in Patients With Acute Coronary Syndrome at High-risk for Ischemia After Percutaneous Coronary Intervention: A Prospective, Randomized, Open-label, Blinded-endpoint Evaluation,Single-center, Phase 3 Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: February 2023

Detailed Description

This is a prospective, randomized, open-label, blinded-endpoint evaluation, single-center Study. There will be 1220 ACS patients at high risk for ischemic events after successful PCI with implantation of at least one drug eluting stent who will be enrolled in Fuwai Hospital, China. Then those included subjects will be randomized to either Ticagrelor plus low-dose Aspirin (50mg daily, LD group) or Ticagrelor plus regular dose Aspirin (75mg daily, control group) for 12 months. The primary endpoint of the current study is to determine the impact of low-dose Aspirin plus Ticagrelor versus standard DAPT for 12 months on major adverse cardiac and cerebral events (MACCEs), and the secondary endpoint is to determine whether the protocol of low dose Aspirin plus Ticagrelor reduces bleeding events, sufficiently inhibits platelet function, and increases the medication adherence among the included patients. In summary, the present study is to provide new evidence and strategy about the anti-platelet protocol for ACS patients at high risk for ischemia.

Interventions

  • Drug: Aspirin
    • Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
  • Drug: Ticagrelor
    • Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)

Arms, Groups and Cohorts

  • Experimental: LD group
    • Low-dose Aspirin(50mg qd) + Ticagrelor( 90mg bid) for 12 months
  • Active Comparator: Control group
    • Regular Aspirin(75mg qd) + Ticagrelor(90mg bid) for 12 months

Clinical Trial Outcome Measures

Primary Measures

  • Major adverse cardiac and cerebral events (MACCEs)
    • Time Frame: 12 months after randomization
    • Number of participants with a composite of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke or urgent target vessel revascularization

Secondary Measures

  • Bleeding episode (Key secondary endpoint)
    • Time Frame: 12 months after randomization
    • Number of participants with major bleeding(Bleeding Academic Research Consortium (BARC) types ≥3) and/or minor bleeding(Bleeding Academic Research Consortium (BARC) types 0-2)
  • Platelet function
    • Time Frame: 12 months after randomization
    • Platelet inhibition, blood level and urine level of thromboxaneB2(TXB2)
  • Medication adherence
    • Time Frame: 12 months after randomization
  • Bleeding-related withdrawal
    • Time Frame: 12 months after randomization

Participating in This Clinical Trial

Inclusion Criteria

  • ACS patients at high risk for ischemic events after successful PCI with implantation of at least one drug eluting stent – Able and willing to provide informed consent and participate in 12 months follow-up period – Able to receive DAPT treatment – Enrollment into the study will require meeting at least one angiographic inclusion and none of the exclusion criteria. Angiographic Inclusion Criteria:

1. LM lesion requiring stents 2. Proximal LAD lesion(s) requiring stents 3. Bypass grafts lesion(s) requiring stents 4. Overall stent length ≥60 mm 5. History of in-stent thrombosis 6. Bifurcation lesions requiring at least 2 stents 7. Over two vessels lesions requiring stents 8. Calcified target lesion(s) requiring atherectomy 9. The intraoperative occurrence of no-reflow or slow-flow 10. Compressed branch vessels with a diameter of at least 2.0 mm failing to reach flow restoration (at least TIMI 3) Exclusion Criteria:

  • Need for chronic oral anticoagulation – With cardiomyopathy(HCM/DCM/RCM) – With severe ventricular arrhythmia requiring ICD implantation – With chronic respiratory disease (COPD, asthma, chronic bronchitis, pulmonary heart disease) – With severe infectious disease(active hepatitis B, active hepatitis C, AIDS) – With hematological disorders(thrombocytopenia, severe anemia, leukaemia) – With severe liver disease or kidney failure – With malignant tumor – With cognitive impairment – Unable or unwilling to provide informed consent or undergo follow-up

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Fu Wai Hospital, Beijing, China
  • Provider of Information About this Clinical Study
    • Principal Investigator: Qian Haiyan, MD, PhD – Fu Wai Hospital, Beijing, China
  • Overall Official(s)
    • Haiyan Qian, MD, PhD, Principal Investigator, Fuwai Hospital, Beijing, China
  • Overall Contact(s)
    • Haiyan Qian, MD, PhD, +8613811386143, ahqhy712@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.